Effect of Octreotide Long-Acting Release on Tregs and MDSC Cells in Neuroendocrine Tumour Patients: A Pivotal Prospective Study
Authors:
- Claudia von ArxCAClaudia von Arx
- Giuseppina ReaGRGiuseppina Rea
- Maria NapolitanoMNMaria Napolitano
- Alessandro OttaianoAOAlessandro Ottaiano
- Fabiana TatangeloFabiana Tatangelo
- Francesco IzzoFIFrancesco Izzo
- Antonella PetrilloAPAntonella Petrillo
- Ottavia ClementeOCOttavia Clemente
- Antonella Di SarnoASAntonella Di Sarno
- Gerardo BottiGBGerardo Botti
- Stefania ScalaStefania Scala
- Salvatore TafutoSalvatore Tafuto
Open Access
Abstract
Octreotide long-acting repeatable (LAR) is largely used to treat functional and/or metastatic neuroendocrine neoplasms (NENs). Its effect in controlling carcinoid syndrome and partially reduce tumour burden is attributable to the ability of octreotide to bind somatostatin receptors (SSTRs) on the tumour and metastasis, regulating growth hormone secretion and cell growth. Notably, SSTRs are also expressed, at different levels, on Tregs. Tregs, together with myeloid-derived suppressor cells (MDSCs), are key components in the anti-tumour immunoregulation. This is the first prospective study aimed to explore the impact of Octreotide (OCT) LAR on the immune system, with a particular focus on Tregs and MDSC cells. Here, we show that circulating Tregs are elevated in NENs patients compared to healthy donors and that treatment with OCT LAR significantly decrease the level of total Tregs and of the three functional Tregs populations: nTregs, eTregs and non-Tregs. Furthermore, OCT LAR treatment induces a functional impairment of the remaining circulating Tregs, significantly decreasing the expression of PD1, CTLA4 and ENTPD1. A trend in circulating MDSC cells is reported in patients treated with OCT LAR. The results reported here suggest that the effect of OCT LAR on Tregs could tip the balance of the patients’ immune-system towards a durable anti-tumour immunosurveillance with consequent long-term control of the NENs disease.Keywords
This publication has 53 references indexed in Scilit:
- Coordinated regulation of myeloid cells by tumoursNature Reviews Immunology, 2012
- CD39/ENTPD1 Expression by CD4+Foxp3+ Regulatory T Cells Promotes Hepatic Metastatic Tumor Growth in MiceGastroenterology, 2010
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cellsJournal of Experimental Medicine, 2009
- Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearanceNature, 2009
- Myeloid-Derived Suppressor Cells: Linking Inflammation and CancerThe Journal of Immunology, 2009
- Adenosine receptors in regulation of dendritic cell differentiation and functionBlood, 2008
- Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppressionJournal of Experimental Medicine, 2007
- FOXP3+ Regulatory T Cells Affect the Development and Progression of HepatocarcinogenesisClinical Cancer Research, 2007
- Tumor infiltrating Foxp3+ regulatory T‐cells are associated with recurrence in pathologic stage I NSCLC patientsCancer, 2006
- Neuroendocrine‐Immune InteractionsAnnals of the New York Academy of Sciences, 2006